Friday December 05 2008 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
  • A-Z

Steve Tomlin joins Cambridge Healthcare & Biotech as a Principal Associate

CAMBRIDGE, UK, August 25, 2003 - Cambridge Healthcare & Biotech Ltd (CH&B) today announced that Steve Tomlin had joined the group as a Principal Associate.

Steve Tomlin has over 30 years experience as a senior HR professional, over 25 of them gained in pharmaceuticals. He joins CH&B from Synavant, where he was HR Director for International. He has also held senior HR positions with IMS Health, SmithKline Beecham, Rhône-Poulenc Rorer and Warner-Lambert. Steve’s track record embraces all aspects of the human and organisational elements of mergers, start-ups and restructuring where he has played a key role in transitioning and change management in numerous situations both within the UK and internationally.


Martyn Postle, Director and Founder of CH&B, said. “Steve is particularly valued by us for his experience in post-acquisition integration and other forms of restructuring. Having Steve on board allows us to offer our clients a soup to nuts service in M&A, from the initial identification of a target, through commercial and technical due diligence and to ensuring that post-acquisition integration is carried out in such a way that the new entity can maximise the benefits of any synergies and is energised for future growth. Steve is the 22nd Associate to join the CH&B team. This size of group, especially when complemented by our US alliance partner Back Bay Strategies, gives us the critical mass to successfully implement major global projects for our clients.”


Cambridge Healthcare & Biotech
Cambridge Healthcare & Biotech is a knowledge-based consultancy serving all sectors of the healthcare industry. The company brings a unique perspective to solving client problems through an in-depth understanding of technology, product development, marketing, healthcare systems and corporate finance which is embedded in its project teams. In particular, the track record of its team in commercial and technical due diligence is second to none, enabling its clients to maximize value and minimize risk in mergers, acquisitions, divestments and licensing transactions.

ENDS

Contact:
Martyn Postle, Director, Cambridge Healthcare & Biotech
Tel: +44 (0) 1223 839 503
Email:
martyn.postle@chandb.com 

Cambridge Healthcare & Biotech Ltd, 18 Duxford Road, Whittlesford, Cambridge CB2 4ND
Tel: +44 (0)1223 839 503 Fax (Europe): +44 (0)8701 330 690 or (USA) +1 413 403 6219
http://www.chandb.com  e-mail: info@chandb.com 


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright © 1997-2008 - BioPortfolio Limited.